The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

2009/06/10 by Dulce Soler, Tobias R. Chapman, Tobias Chapman +5 · 27 citations
Immunology and Microbiology · Medicine · #Addressin #Antibody #Biochemistry #Biology #CD8 #Immune Cell Function and Interaction #Immune system #Immunodeficiency and Autoimmune Disorders #Immunology #Integrin #Internal medicine #Medicine #Molecular biology #Monoclonal antibody #Receptor #T cell #T-cell and B-cell Immunology #Ulcerative colitis #Vedolizumab

paper · doi:10.1124/jpet.109.153973

openalex publication_date 2009/06/10 · openalex created_date 2016/06/24 · openalex updated_date 2026/08/06

Cited by

• Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7–Blocking Therapy in Inflammatory Bowel Disease
• Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
• Blocking of α4β7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. [europepmc]
• Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion. [europepmc]
• Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. [europepmc]
• The multifaceted mast cell in inflammatory bowel disease. [europepmc]
• The safety of vedolizumab for ulcerative colitis and Crohn's disease. [europepmc]
• The Dual Role of Neutrophils in Inflammatory Bowel Diseases. [europepmc]
• Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. [europepmc]
• Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. [europepmc]
• Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. [europepmc]
• A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. [europepmc]
• Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. [europepmc]
• Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. [europepmc]
• Non-Provitamin A and Provitamin A Carotenoids as Immunomodulators: Recommended Dietary Allowance, Therapeutic Index, or Personalized Nutrition? [europepmc]
• Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. [europepmc]
• Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. [europepmc]
• Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function. [europepmc]
• The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. [europepmc]
• Ulcerative Colitis: Current and Emerging Treatment Strategies. [europepmc]
• Contributions of Eosinophils to Human Health and Disease. [europepmc]
• Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. [europepmc]
• Blocking integrin α 4 β 7 -mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis. [europepmc]
• Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies. [europepmc]
• Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. [europepmc]
• Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. [europepmc]
• T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor. [europepmc]